Transcytosis– tag –
-
Caltech Unveils ‘BrainCAB’ Molecular Shuttle for Enhanced Blood-Brain Barrier Drug Delivery Targeting Carbonic Anhydrase IV
Caltech News USA Overview Caltech researchers have developed 'BrainCAB,' a novel molecular shuttle that efficiently crosses the blood-brain barrier (BBB) to deliver drugs to the brain. This technology utilizes a small molecule shuttle th... -
Alcimed Analyzes Brain Drug Delivery Barriers and Breakthroughs: Receptor-Mediated Transcytosis and LIFU as Key Enablers
Alcimed France Overview Brain drug delivery is one of modern medicine's most complex challenges due to multiple physiological barriers, notably the blood-brain barrier (BBB), which severely restricts most therapeutic molecules from enter... -
Breaking the Blood-Brain Barrier: Nanoparticles Chart New Course for Neurodegenerative Therapies
Dove Medical Press New Zealand Overview The blood-brain barrier (BBB) prevents over 98% of small-molecule drugs and nearly all biologics from entering the brain, posing a major challenge for neurological therapies. Nanoparticles (NPs) of... -
Engineered Antibody Brainshuttle™ Technology Boosts Brain Drug Delivery of RNA-Based ASOs by Dual-Targeting TfR1 and CD98hc Receptors, Illuminating CNS Disease Treatment
EMJ Unknown Overview Antibody-based Brainshuttle™ technology has made significant strides in brain drug delivery for promising therapeutics like RNA-based antisense oligonucleotides (ASOs), which are otherwise unable to cross the blood-b... -
FDA Grants Accelerated Approval to AVLAYAH, a BBB-Penetrating Biologic, Ushering in a New Era for Brain Drug Delivery
Drug Delivery Leader USA Overview On March 25, 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), the first biologic engineered to traverse the blood-brain barrier (BBB). This landmark decision, following dec...
1